Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Odanacatib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK known ✓ | P43235 | 16/20 | 1.00 |
| ▸ | CTSL | P07711 | 8/20 | 1.00 |
| ▸ | CTSB | P07858 | 7/20 | 1.00 |
| ▸ | CTSS | P25774 | 5/20 | 1.00 |
| ▸ | CTSF | Q9UBX1 | 3/20 | 1.00 |
| ▸ | CTSV | O60911 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Odanacatib SCHEMBL1496266 | 1.00 | CTSK (1.00) | CTSKCTSLCTSBCTSSCTSF | |
| Odanacatib SCHEMBL18540595 | 1.00 | CTSK (1.00) | CTSKCTSLCTSBCTSSCTSF | |
| Odanacatib SCHEMBL15827397 | 1.00 | CTSK (1.00) | CTSKCTSLCTSBCTSSCTSF | |
| SCHEMBL2155573 | 0.94 | CTSK (0.90) | CTSKCTSLCTSBCTSSCTSF | |
| Odanacatib SCHEMBL21828714 | 0.94 | CTSK (0.88) | CTSKCTSLCTSBCTSSCTSF | |
| Odanacatib SCHEMBL21828716 | 0.94 | CTSK (0.88) | CTSKCTSLCTSBCTSSCTSF | |
| SCHEMBL2155279 | 0.94 | CTSK (0.88) | CTSKCTSLCTSBCTSSCTSF | |
| SCHEMBL2156790 | 0.92 | CTSK (0.85) | CTSKCTSLCTSBCTSSCTSF | |
| SCHEMBL22733918 | 0.91 | CTSK (0.83) | CTSKCTSLCTSBCTSSCTSF | |
| SCHEMBL22733917 | 0.91 | CTSK (0.83) | CTSKCTSLCTSBCTSSCTSF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148179-A1 | SMALL MOLECULE INHIBITORS OF SARS-CoV-2 VIRAL REPLICATION AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| US-20210300863-A1 | PROCESS TO MAKE A SELECTIVE CATHEPSIN CYSTEINE PROTEASE INHIBITOR | INTERVET INC. (US) | 2021-09-30 | — | — | US | disclosed |
| EP-2144871-A1 | AMIDATION PROCESS FOR THE PREPARATION OF CATHEPSIN K INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008119176-A1 | AMIDATION PROCESS FOR THE PREPARATION OF CATHEPSIN K INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148179-A1 | SMALL MOLECULE INHIBITORS OF SARS-CoV-2 VIRAL REPLICATION AND USES THEREOF | ACE2, ACE, SARS1 | CTSK 86/4885CTSL 6/4885CTSB 31/4885 |
| US-20210300863-A1 | PROCESS TO MAKE A SELECTIVE CATHEPSIN CYSTEINE PROTEASE INHIBITOR | CTSB, CTSF, CTSZ | CTSK 8/4885CTSL 11/4885CTSB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.